Recently, we have shown that inhibition of the coagulation factor Xa (FXa) with the oral, direct and specific FXa inhibitor rivaroxaban reduced right ventricular (RV) hypertrophy and dysfunction in monocrotaline (MCT)-induced pulmonary hypertension [6], suggesting that activation of coagulation factors is involved in disease progression. The gene discussed is F10; the disease is pulmonary arterial hypertension.